Equity
AOCI
Alnylam Pharmaceuticals AOCI decreased by 23.9% to -$24.89M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.6%, from -$37.52M to -$24.89M. Over 5 years (FY 2020 to FY 2025), AOCI shows an upward trend with a -14.4% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
Metric ID:
aociHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$36.08M | -$34.23M | -$33.26M | -$38.07M | -$42.22M | -$43.78M | -$44.65M | -$39.12M | -$37.08M | -$32.34M | -$23.38M | -$26.99M | -$34.64M | -$24.83M | -$34.52M | -$37.52M | -$29.95M | -$21.78M | -$20.10M | -$24.89M |
| QoQ Change | — | +5.1% | +2.8% | -14.5% | -10.9% | -3.7% | -2.0% | +12.4% | +5.2% | +12.8% | +27.7% | -15.5% | -28.3% | +28.3% | -39.0% | -8.7% | +20.2% | +27.3% | +7.7% | -23.9% |
| YoY Change | — | — | — | — | -17.0% | -27.9% | -34.3% | -2.8% | +12.2% | +26.1% | +47.7% | +31.0% | +6.6% | +23.2% | -47.7% | -39.0% | +13.5% | +12.3% | +41.8% | +33.6% |
Range-$44.65M – -$20.10M
CAGR-7.5%
Avg YoY Growth+5.0%
Median YoY Growth+12.2%
AOCI at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's aoci?
- Alnylam Pharmaceuticals (ALNY) reported aoci of -$24.89M in Q1 2026.
- How has Alnylam Pharmaceuticals's aoci changed year-over-year?
- Alnylam Pharmaceuticals's aoci increased by 33.6% year-over-year, from -$37.52M to -$24.89M.
- What is the long-term trend for Alnylam Pharmaceuticals's aoci?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's aoci has grown at a -14.4% compound annual growth rate (CAGR), from -$43.62M to -$20.10M.